180 related articles for article (PubMed ID: 15777350)
21. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
Stajszczyk M
Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
[No Abstract] [Full Text] [Related]
22. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
23. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
24. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
[No Abstract] [Full Text] [Related]
25. Multiple myeloma.
Schneider HG; Sentry J
N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
[No Abstract] [Full Text] [Related]
26. RANKing the importance of measles virus in Paget's disease.
Ross FP
J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
[No Abstract] [Full Text] [Related]
27. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
Kostenuik PJ
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
[No Abstract] [Full Text] [Related]
28. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
29. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
Choi JY; Shin A; Park SK; Chung HW; Cho SI; Shin CS; Kim H; Lee KM; Lee KH; Kang C; Cho DY; Kang D
Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677
[TBL] [Abstract][Full Text] [Related]
30. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity.
Elhasid R; Hofbauer LC; Ish-Shalom S; Ben-Arush M; Koc O; Rowe JM; Etzioni A
Am J Hematol; 2003 Jan; 72(1):34-7. PubMed ID: 12508266
[TBL] [Abstract][Full Text] [Related]
31. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
Mori T; Oguro A; Ohtsu T; Nakamura Y
Nucleic Acids Res; 2004; 32(20):6120-8. PubMed ID: 15562003
[TBL] [Abstract][Full Text] [Related]
32. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
33. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
Hofbauer LC; Heufelder AE; Erben RG
J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
[No Abstract] [Full Text] [Related]
35. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
36. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
37. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models.
Neumann E; Gay S; Müller-Ladner U
Arthritis Rheum; 2005 Oct; 52(10):2960-7. PubMed ID: 16200575
[No Abstract] [Full Text] [Related]
38. [Recent advance in basic research for osteoporosis].
Suda T; Miyaura C
Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
[No Abstract] [Full Text] [Related]
39. The role of the immune system in the pathophysiology of osteoporosis.
Clowes JA; Riggs BL; Khosla S
Immunol Rev; 2005 Dec; 208():207-27. PubMed ID: 16313351
[TBL] [Abstract][Full Text] [Related]
40. RANK ligand and the regulation of skeletal remodeling.
Bell NH
J Clin Invest; 2003 Apr; 111(8):1120-2. PubMed ID: 12697730
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
